Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis.

Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH.

Am J Respir Crit Care Med. 2010 Feb 1;181(3):254-63. doi: 10.1164/rccm.200810-1615OC. Epub 2009 Oct 22.

2.

Determinants of initiation and progression of idiopathic pulmonary fibrosis.

Kottmann RM, Hogan CM, Phipps RP, Sime PJ.

Respirology. 2009 Sep;14(7):917-33. doi: 10.1111/j.1440-1843.2009.01624.x. Review.

3.

Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases.

Weitzenblum E, Chaouat A, Canuet M, Kessler R.

Semin Respir Crit Care Med. 2009 Aug;30(4):458-70. doi: 10.1055/s-0029-1233315. Epub 2009 Jul 24. Review.

PMID:
19634085
4.

Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis.

Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W, Sherrill TP, Plieth D, Neilson EG, Blackwell TS, Lawson WE.

Am J Respir Crit Care Med. 2009 Oct 1;180(7):657-65. doi: 10.1164/rccm.200903-0322OC. Epub 2009 Jun 25.

5.

Emerging concepts in the pathogenesis of lung fibrosis.

Hardie WD, Glasser SW, Hagood JS.

Am J Pathol. 2009 Jul;175(1):3-16. doi: 10.2353/ajpath.2009.081170. Epub 2009 Jun 4. Review.

6.

Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis.

Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, Kim DS, Kaminski N.

Am J Respir Crit Care Med. 2009 Jul 15;180(2):167-75. doi: 10.1164/rccm.200810-1596OC. Epub 2009 Apr 10. Erratum in: Am J Respir Crit Care Med. 2009 Aug 15;180(4):380.

7.

Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis.

Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, Hardie WD.

Am J Respir Cell Mol Biol. 2009 Nov;41(5):562-72. doi: 10.1165/rcmb.2008-0377OC. Epub 2009 Feb 24.

8.

Therapies for interstitial lung disease: past, present and future.

Kim R, Meyer KC.

Ther Adv Respir Dis. 2008 Oct;2(5):319-38. doi: 10.1177/1753465808096948. Review.

PMID:
19124380
9.

Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis.

Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML, Frank JA, Brumwell AN, Wheeler SE, Kreidberg JA, Chapman HA.

J Clin Invest. 2009 Jan;119(1):213-24. doi: 10.1172/JCI36940. Epub 2008 Dec 22.

10.

Epithelial-mesenchymal transition.

Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E.

Cancer Res. 2008 Dec 1;68(23):9574-7. doi: 10.1158/0008-5472.CAN-08-2316. No abstract available.

11.

Increased circulating fibrocytes in asthma with chronic airflow obstruction.

Wang CH, Huang CD, Lin HC, Lee KY, Lin SM, Liu CY, Huang KH, Ko YS, Chung KF, Kuo HP.

Am J Respir Crit Care Med. 2008 Sep 15;178(6):583-91. doi: 10.1164/rccm.200710-1557OC. Epub 2008 Jun 26.

PMID:
18583572
12.

Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Xia H, Diebold D, Nho R, Perlman D, Kleidon J, Kahm J, Avdulov S, Peterson M, Nerva J, Bitterman P, Henke C.

J Exp Med. 2008 Jul 7;205(7):1659-72. doi: 10.1084/jem.20080001. Epub 2008 Jun 9.

13.

EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.

Hardie WD, Davidson C, Ikegami M, Leikauf GD, Le Cras TD, Prestridge A, Whitsett JA, Korfhagen TR.

Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1217-25. doi: 10.1152/ajplung.00020.2008. Epub 2008 Apr 18.

PMID:
18424623
14.

Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis.

Laurent GJ, McAnulty RJ, Hill M, Chambers R.

Proc Am Thorac Soc. 2008 Apr 15;5(3):311-5. doi: 10.1513/pats.200710-159DR.

15.

Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis.

Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramírez R, Pardo A, Westergren-Thorsson G, Selman M.

Int J Biochem Cell Biol. 2008;40(10):2129-40. doi: 10.1016/j.biocel.2008.02.012. Epub 2008 Mar 11.

PMID:
18374622
16.

Dual-immunohistochemistry provides little evidence for epithelial-mesenchymal transition in pulmonary fibrosis.

Yamada M, Kuwano K, Maeyama T, Hamada N, Yoshimi M, Nakanishi Y, Kasper M.

Histochem Cell Biol. 2008 Apr;129(4):453-62. doi: 10.1007/s00418-008-0388-9. Epub 2008 Jan 31.

PMID:
18236067
17.

Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.

Krämer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H.

Am J Physiol Renal Physiol. 2008 Feb;294(2):F440-9. Epub 2007 Dec 19.

PMID:
18094032
18.

Therapeutic potential of stem cells in lung disease: progress and pitfalls.

Loebinger MR, Aguilar S, Janes SM.

Clin Sci (Lond). 2008 Jan;114(2):99-108. Review.

PMID:
18062775
19.

Rapamycin: something old, something new, sometimes borrowed and now renewed.

Hartford CM, Ratain MJ.

Clin Pharmacol Ther. 2007 Oct;82(4):381-8. Epub 2007 Aug 29. Review.

PMID:
17728765
20.

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J.

Am J Nephrol. 2007;27(5):495-502. Epub 2007 Jul 20.

PMID:
17671379

Supplemental Content

Support Center